Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing

Editas Medicine, Inc.

Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.
Reduces workforce by ~180 positions (65%); costs of $55-70M for discontinuation, $14-18M for reduction.
Cash runway extended to Q2 2027; focuses on in vivo pipeline, with human proof-of-concept target in ~2 years.
CMO Baisong Mei steps down Dec 31; board members Emma Reeve and Meeta Chatterjee resign; Jessica Hopfield becomes Chair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.